DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CRIZOTINIB

« Back to Dashboard

Clinical Trials for Crizotinib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00939770	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma.
NCT00939770	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Active, not recruiting	Children's Oncology Group	Phase 1/Phase 2	RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma.
NCT01082380	Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers	Completed	Pfizer	Phase 1	The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans.
NCT01121588	An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)	Active, not recruiting	Pfizer	Phase 1	This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.

Clinical Trial Conditions for Crizotinib

Condition Name

Condition Name for Crizotinib
Intervention	Trials
Non-small Cell Lung Cancer	23
Healthy	10
Carcinoma, Non-Small-Cell Lung	6
Lung Cancer	5

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Crizotinib
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	52
Lung Neoplasms	46
Lymphoma	14
Neoplasms	12

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Crizotinib

Trials by Country

Trials by Country for Crizotinib
Location	Trials
United States	599
Italy	78
Japan	63
China	53
Spain	50

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Crizotinib
Location	Trials
California	28
Texas	28
Florida	25
Massachusetts	24
Ohio	22

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Crizotinib

Clinical Trial Phase

Clinical Trial Phase for Crizotinib
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	14
Phase 2	49

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Crizotinib
Clinical Trial Phase	Trials
Recruiting	52
Active, not recruiting	22
Not yet recruiting	19

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Crizotinib

Sponsor Name

Sponsor Name for Crizotinib
Sponsor	Trials
Pfizer	44
National Cancer Institute (NCI)	11
Hoffmann-La Roche	8

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Crizotinib
Sponsor	Trials
Other	113
Industry	91
NIH	11

Export unavailable in trial.
Subscribe for complete access.